- |||||||||| Melflufen (melphalan flufenamide) / Oncopeptides
OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators () - Nov 29, 2022 - Abstract #ASH2022ASH_7729;
Method s :Eligible patients with RRMM had received 2-4 prior lines of therapy (LoTs), including lenalidomide (len) and a proteasome inhibitor, and were refractory to len and to the last LoT...Patients refractory to prior alkylators had received cyclophosphamide (melflufen, 81%; pom, 69%), standard dose melphalan (<140 mg/m2; melflufen, 19%; pom, 31%), and/or bendamustine (melflufen, 4%; pom, 5%)...The safety profile of melflufen + dex in patients with disease refractory to prior alkylators was consistent with previous reports.Conclusion :Melflufen + dex was associated with higher PFS and OS compared with pom + dex in patients with RRMM who had disease refractory to prior alkylators, with no new safety signals identified in the patient population. These results suggest that melflufen is safe and effective in patients who are alkylator-refractory, regardless of whether they received a prior ASCT or not.
- |||||||||| Tecvayli (teclistamab) / Genmab, J&J
Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program () - Nov 29, 2022 - Abstract #ASH2022ASH_7727;
Tocilizumab was only administrated to the patient with CRS grade 2...COVID-19 infections were treated with sotrovimab, remdesivir and/or corticosteroids...Therefore, regular monitoring of infections including viral reactivation is important. Hypogammaglobulinemia should be treated with immunoglobulin replacement therapy and prophylaxis against herpes simplex virus/varicella zoster virus and hepatitis B (in serologically HBV positive patients without active infection) is recommended.
- |||||||||| Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Real-World Safety and Effectiveness of Selinexor-Based Regimens in Patients with Relapsed or Refractory Multiple Myeloma and Dialysis-Dependent Renal Impairment () - Nov 29, 2022 - Abstract #ASH2022ASH_7725;
P3
Selinexor, a first-in-class oral selective inhibitor of nuclear exportin 1 approved in combination with dexamethasone (Xd) and dexamethasone+bortezomib (XVd, approved relapsed/refractory MM [RRMM] after at least one prior therapy), has several characteristics that make it a promising therapy in pts with MM and RI...Patient details were obtained via a validated portal system and from the treating physicians.Result s : Between March 2020 to June 2022, 15 pts were treated with selinexor-based regimens, including Xd, XVd, Xd+pomalidomide (XPd), and Xd+carfilzomib (XKd) (Table 1)...Prior therapies included at least 1 PI (100%), at least 1 IMiD (100%), daratumumab (86.7%), and autologous stem cell transplant (46.7%)...The ORR was 40% despite previous anti-MM treatments with 86.7% of pts having TCT MM. Taken together, these results suggest the real-world effectiveness and tolerability of selinexor regimens in a challenging-to-treat patient population.
- |||||||||| Darzalex (daratumumab) / J&J
Real-World Outcome of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter Propensity Score Matched Case Series Study () - Nov 29, 2022 - Abstract #ASH2022ASH_7720;
Major trials in patients with relapsed/refractory multiple myeloma (RRMM), CASTOR, POLLUX, APOLLO, and CANDOR, has proved benefits in both progression free survival (PFS) and response rate in favor of daratumumab incorporation into proteasome inhibitors (PI) or immunomodulatory agents (IMiDs) and dexamethasone doublet regimen. The median PFS time were 15.2 months in control arm versus unreached in daratumumab arm (p0.05).Conclusion In our real-world propensity score matched data, we confirmed that daratumumab incorporation of MM care could provide significant response and progression free survival benefits.Figure legend: A. Progression free survival and B. overall survival of patients with RRMM receiving daratumumab-based regimens and conventional regimens (control arm).
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era () - Nov 29, 2022 - Abstract #ASH2022ASH_7718;
In particular, for 11 patients, BVD was, after having achieved at least a PR, a bridge to second auSCT, and for two patients a bridge to alloSCT. Eight patients have surprisingly achieved a notable PR after failure of novel agents (i.e. Carfilzomib, Daratumumab and Pomalidomide).Median time to response was 1.3 months (r.1-3), median OS from diagnosis was 67.3 months (r.6-151), median OS from start of Bendamustine was 9.6 months (r.2-36).The triplet Bendamustine-Bortezomib-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT, also after failure of novel agents.
- |||||||||| Light Chain(AL) Cardiac Amyloidosis: A Real World Data on Therapy and Outcomes () - Nov 29, 2022 - Abstract #ASH2022ASH_7715;
The study, which is probably the first of its kind from tertiary cancer care centres in South Asian region , throws light on the need for comparative cardiac monitoring using global longitudinal ECHO , cardiac MRI and statistically significant benefits in subsequent assessments and progression free survival with CyBorD. Consequential to other significant findings, it may be true to state that early cardiac imaging and initiation of CyBorD can contribute to superior outcomes in cardiac amyloidosis diagnosed in early stages.
- |||||||||| Darzalex (daratumumab) / J&J, Mozobil (plerixafor) / Sanofi
Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution () - Nov 29, 2022 - Abstract #ASH2022ASH_7714;
Intermediate-dose cyclophosphamide (3-4 g/m2) + G-SCF was the PBSC mobilizing schema in 98% of patients, with successful harvest in 97%...Administration of plerixafor was required in 5.8% of patients...High dose melphalan was the conditioning regimen for all ASCT, with 200 mg/msq in 85% of cases; in unfit patients (15%), the dose was reduced to 140 mg/msq (100 mg/msq in one case)...Six patients were diagnosed with a secondary malignancy (3 breast cancers, 1 colon cancer, 1 MDS and 1 oral cavity cancer).In conclusion, VTD followed by ASCT in real life resulted in excellent and durable responses in untreated and fit MM patients, with the large majority not requiring further therapy after a median follow-up of more than 4 years. The recent addition of daratumumab to the first line regimen is expected to further improve patient outcomes.
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Clinician and Patient Perspectives on Treatment Decision-Making in Multiple Myeloma: A Qualitative Survey () - Nov 29, 2022 - Abstract #ASH2022ASH_7691;
In the current study, both pts and HEM/ONCs prioritized disease control over most other aspects, particularly in later lines. Pts and HEM/ONCs prioritized maintaining quality of life over avoiding specific adverse events that are not life-threatening or requiring medical intervention.
- |||||||||| Darzalex (daratumumab) / J&J, marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
How to Treat Isolated Leptomeningeal Relapse of Multiple Myeloma 11 Years after Autologous Stem Cell Transplantation (ASCT) () - Nov 29, 2022 - Abstract #ASH2022ASH_7673;
In addition to corticosteroids, there is clinical evidence that thalidomide crosses the blood-brain barrier (BBB), in murine models pomalidomide also has good penetration into the CNS...Among proteasome inhibitors, only marizomib has been observed to cross the BBB in a murine model, while bortezomib does not...It is not known if weekly doses of daratumumab could attain therapeutic levels in CSF.We found only 14 cases of isolated CNS relapse in patients with MM treated with ASCT with a median interval between transplant and relapse of 3 months (0.5-96m), with only one reported relapse 7.5 years after autologous transplant and the median overall survival was only 3 months...We conclude that the systemic use of pomalidomide and dexamethasone should be the best approach of MM isolated CNS relapse. Further investigations will clarify if other novel drugs are active in this context.
- |||||||||| Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies () - Nov 29, 2022 - Abstract #ASH2022ASH_7668;
Treatment was switched to isatuximab/pomalidomide/dexamethasone...Lymphodepletion with fludarabine/cyclophosphamide according to the phase-II KarMMa protocol was initiated, and 441.5 x 10exp6 CAR T-cells were infused...Two weeks after infusion of Ide-cel, significant increases of serum uric acid and lactate dehydrogenase levels indicative of tumor lysis syndrome were detected, requiring application of rasburicase and intravenous hydration...This demonstrates that sequential treatment can be effective even after multiple prior lines of anti-BCMA directed therapies. Patients with prior exposure to anti-BCMA agents should have access to anti-BCMA CAR T-cells.
- |||||||||| Darzalex (daratumumab) / J&J
Real-World Treatment Patterns of Patients Initiating Third-Line Therapy in Relapsed or Refractory Multiple Myeloma in Europe () - Nov 29, 2022 - Abstract #ASH2022ASH_7665;
The most common 2L treatment regimens were lenalidomide (LEN) + DEX (Rd; 30%), Vd (11%), and carfilzomib (CFZ) + Rd (8%)...In 3L, combinations were often based on LEN and/or CFZ with daratumumab (DARA) monotherapy and pomalidomide (POM) + DEX (Pd) also contributing about 4% each (Table).In Italy, common 1L regimens included MEL ± DEX ± PRED (22%), Vd (6%), and thalidomide (THAL) + DEX (5%)...Comparisons with more recent index groups could help elucidate treatment evolution over time. Additionally, it would be relevant to understand how European RW clinical practice compares with observations in the US setting.
- |||||||||| Farydak (panobinostat) / Secura Bio
Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients () - Nov 29, 2022 - Abstract #ASH2022ASH_7664;
Panobinostat (pano) is an oral pan histone-deacetylase (HDAC) inhibitor which improves outcomes when added to bortezomib and dexamethasone for multiple myeloma in early relapse and even re-sensitizes myeloma to proteasome inhibitors...Pano was combined with steroids along with a 3rd and sometimes 4th drug, most commonly with lenalidomide, pomalidomide, carfilzomib, and daratumumab in descending order of utilization...As a convenient oral option with a unique mechanism of action, pano may play an important role in recapturing responses in patients who have relapsed beyond standard therapies. The utility of pano in combination with IMiDs, in particular, warrants further investigation.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
Prevalence of t(11; 14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study () - Nov 29, 2022 - Abstract #ASH2022ASH_7663;
P=N/A, P3
Venetoclax (Ven) is a selective and potent oral B-cell lymphoma-2 (BCL-2) inhibitor that has shown significant antimyeloma activity in patients with t(11; 14) RRMM (Kumar et al...In the phase 3 BELLINI (NCT02755597) study, patients with t(11; 14) RRMM showed improved response rates and progression-free survival when treated with Ven in combination with bortezomib and dexamethasone compared to placebo-bortezomib-dexamethasone (Kumar et al...An ongoing phase 3 study, CANOVA (NCT03539744), is evaluating the combination of Ven and dexamethasone in patients with t(11; 14) RRMM compared to standard of care pomalidomide-dexamethasone (Mateos et al...There were 8 patients with unknown stage of disease, 3 among them were t(11; 14)+.Conclusion : Interim analysis of MEDICI demonstrated that prevalence of t(11; 14) was consistent across ND and RRMM setting and independent of line of therapy and disease stage. This study is currently ongoing, and further updates will be provided upon presentation.
- |||||||||| Vonjo (pacritinib) / CTI BioPharma
The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients () - Nov 29, 2022 - Abstract #ASH2022ASH_7648;
Previously, we have shown the JAK1/2 inhibitor ruxolitinib has beneficial effects for treating multiple myeloma (MM) patients...Specifically, we examined the anti-proliferative effects of pacritinib alone and in combination with dexamethasone, pomalidomide or bortezomib using these 3 MM cell lines and 1 patient's fresh MM BMMCs...We also show the anti-MM effects of pacritinib both alone and in combination with other anti-MM drugs. Pacritinib can be potentially beneficial for treating myeloma patients due to its inhibitory role on PVRIG and TIGIT expression which may enhance tumor cell killing by CD8+ T cells.
- |||||||||| High Mutational Burden of Chromatin-Modifying Genes Defines a Relatively Indolent Subgroup of Plasma Cell Dyscrasias () - Nov 29, 2022 - Abstract #ASH2022ASH_7645;
Also, the patients with MM or AL of the CMGmut subgroup showed inferior responses to the first-line CyBorD (cyclophosphamide, bortezomib, and dexamethasone), whereas the patients with MM of the CMGmut subgroup showed non-inferior responses to the first-line VRD (bortezomib, lenalidomide, and dexamethasone).In summary, TGS panel-based mutational profiling provided mechanistic insights into a subgroup of patients with PCDs characterized by a high mutational burden of chromatin-modifying genes and relatively indolent clinical features. Our findings enable the identification of these patients who will potentially benefit from epigenetic therapy in future clinical management.
- |||||||||| dexamethasone injection / Generic mfg.
Comparison of Dexamethasone Versus Prednisolone Prephase in Induction Therapy of Pediatric Acute Lymphoblastic Leukemia: A Single-Center, Randomized Controlled Study from India () - Nov 29, 2022 - Abstract #ASH2022ASH_7334;
Patients who were randomized to dexamethasone prephase group received intravenous dexamethasone 10 mg/m2/day on days 1-7 of induction,& those in prednisolone prephase group received prednisolone 60 mg/m2/day p.o. in three divided doses on days 1-7 of induction therapy .All the patients subsequently received prednisolone 60 mg/m2/day p.o. in three divided doses on days 8 - 28 of induction, followed by prednisolone taper over next 7 days...To our knowledge, this is the only study to compare dexamethasone versus prednisolone prephase in pediatric ALL induction, in the context of ALL IC-BFM 2009 regimen. Long-term follow up and enrollment of larger number of patients is planned.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study () - Nov 29, 2022 - Abstract #ASH2022ASH_7332;
Twenty-nine (87 %) patients received levetiracetam for seizure-prophylaxis.MRD was measured after each cycle by RT-qPCR with a sensitivity of 10-4 for clonal IgH and for BCR-ABL.As MRD response was considered clonal IgH or BCR-ABL < 10-4.Relapse-free survival (RFS) and overall survival (OS) were estimated by the Kaplan-Meier analysis and compared by the log-rank across the sub-groups using 95 % confidence intervals...MRD-responsive gain a significant survival advantage over non-responsive patients. This advantage was observed both for transplanted and non-transplanted patients.
- |||||||||| dexamethasone / Generic mfg., imatinib / Generic mfg., dasatinib / Generic mfg.
Biological, Functional and Genetic Characterization of Bone Marrow Mesenchymal Stromal Cells from Adult Ph+ Acute Lymphoblastic Leukemia () - Nov 29, 2022 - Abstract #ASH2022ASH_7149;
MSCs derived from different disease status have protective effects on the apoptosis of SUP-B15 induced by drugs, the effects of DR-MSCs and ND-MSCs were stronger than that of CR-MSCs. The protective effect may be achieved through the activity of BMP/SMADs signaling pathway.Figure Legend: A. In Vitro proliferation of MSCs; B.The effect of MSCs cells on apoptosis of SUP-B15; C.Differential gene expression thermogram of DR-MSCs and ND-MCSs; D.Differential gene expression thermogram of ND-CR compared samples.
- |||||||||| dexamethasone / Generic mfg., daunorubicin / Generic mfg., cytarabine / Generic mfg.
Outcomes of Granulocyte Transfusion in Haematology Patients with Febrile Neutropenia - a Single Centre Retrospective Cross Sectional Study () - Nov 29, 2022 - Abstract #ASH2022ASH_7069;
This might have been due to the limited number of patients in both the cohorts.The study is also limited by the retrospective design.Since the study cohort and the control cohort received treatment in two different time periods, there could have been a difference in the supportive care . Inspite of all these limitations our findings may point towards the need for conducting a prospective Randomised controlled trial in patients with very severe neutropenia (ANC<0.2x 10^9/L) and other potential risk factors for MDR infections.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Rituximab in the Treatment of Refractory Heparin Induced Thrombocytopenia () - Nov 29, 2022 - Abstract #ASH2022ASH_7041;
Given the rarity of HIT, there are no management guidelines for the treatment of refractory disease, and such cases remain a challenging clinical scenario. More work is needed to understand if all cases of refractory HIT have an autoimmune component and the role of Rituximab.
- |||||||||| External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs () - Nov 29, 2022 - Abstract #ASH2022ASH_7018;
The SAVED score was calculated at IMiD initiation according to the following five parameters: surgery within last 90 days (+2), Asian race (-3), prior VTE history (+3), age ≥80 years (+1), dexamethasone use (+2 for high dose [>160 mg/30-day], or +1 for standard dose [120-160 mg/30-day])...Most patients (94%) received lenalidomide, whereas 14 (3%) and 15 (3%) patients were treated with thalidomide and pomalidomide, respectively...In contrast to other risk models that focused on all patients with MM, the SAVED score was derived and now validated specifically for patients starting IMiD as this it is the only cancer population with a strong guideline recommendation for ambulatory thromboprophylaxis. Future prospective validation would be useful to determine the predictive nature of SAVED while evaluating safety and efficacy of thromboprophylaxis with direct oral anticoagulant in high-risk patients.
- |||||||||| dexamethasone / Generic mfg., prednisone / Generic mfg.
COVID-19 Vaccination Associated Severe Immune Thrombocytopenic Purpura () - Nov 29, 2022 - Abstract #ASH2022ASH_6998;
He was discharged with prednisone 40 milligrams daily...The Centers for Disease Control and Prevention and US-Food and Drug Administration (FDA) have recently announced that the incidence of ITP after COVID-19 vaccination was not higher than that of the general population.ITP associated with vaccination varies in severity but generally responds well to typical ITP therapies, such as corticosteroids and IVIG. More studies are needed to determine the best treatment options for these patients.
- |||||||||| dexamethasone / Generic mfg.
High Dose Dexamethasone and Early Use of TPO Ras in Newly Diagnosed ITP () - Nov 29, 2022 - Abstract #ASH2022ASH_6993;
There is a controversy about a choice of "better" corticosteroid between prednisone and dexamethasone...As second line treatment patients received eltrombopag (10), romiplostim (6) or other treatments (4), one patient was not treated further...Unfortunately, in many countries TPO RAs are not available for treatment of newly diagnosed and persistent ITP. Further data from studies of early use of TPO RAs from real world practice are needed.
- |||||||||| dexamethasone / Generic mfg.
Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India () - Nov 29, 2022 - Abstract #ASH2022ASH_6991;
No significant difference was noticed between the prednisolone or the dexamethasone group either in terms of treatment outcomes or treatment-related adverse events.Conclusion : Our study shows comparable results between prednisolone and dexamethasone groups in initial and sustained response rates to first-line therapy in newly diagnosed ITP patients but a high incidence 88% of treatment-related adverse events in both groups. A shorter duration of steroids and affordable newer modalities of therapy in ITP is required to improve the overall well-being of ITP patients with lower middle income in India.Disclosures: No relevant conflicts of interest to declare.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Hemophagocytic Lymphohystiocytosis in a Patient with Post-Acute COVID-19 Infection () - Nov 29, 2022 - Abstract #ASH2022ASH_6951;
The patient did have a bone marrow biopsy two months prior to presentation which was unremarkable for hematologic malignancy or features suggestive of HLH such as hemophagocytosis.In view of the patient's high H score and clinical suspicion for HLH, he was initiated on dexamethasone 20 mg daily...Over the course of the hospitalization, WBC count continued to drop with critically low absolute neutrophil counts prompting initiation of Filgrastim.No noticeable clinical improvement was noted over the subsequent days of hospitalization, and the patient was subsequently trialed on an intravenous immunoglobulin protocol for 3 days.Despite all treatment offered, the patient continued to deteriorate and after consultation with family members and the palliative care team, patient was transitioned to comfort measures only and code status was changed to DNR/DNI...Notably, the severity of the COVID-19 infection does not appear to be related to one's predisposition to develop sHLH. Regardless of etiology, the mortality of HLH remains high even with appropriate therapy, especially with neurologic involvement and markedly elevated ferritin levels.
- |||||||||| Hemophagocytic Lymphohistiocytosis Clinical Features and Outcomes: Single Institution Case Series () - Nov 29, 2022 - Abstract #ASH2022ASH_6950;
The current management guidelines based on HLH-94 studies involve immunosuppression with weekly chemotherapy (etoposide) and glucocorticoids (dexamethasone), intrathecal methotrexate is administered in patients with CNS involvement...Two out of nine (22%) patients had been on immunosuppressive therapy prior to diagnosis; one on maintenance prednisone for SLE, and the other on dexamethasone for intracranial tumor...Optimizing diagnostic criteria for earlier detection may benefit both children and adults. Experience with novel agents such as JAK inhibitors and anti-IL-6 during covid pandemic or with T-cell cellular therapies to control the cytokine storms would be an interesting target to study their efficacy in HLH prospectively.
- |||||||||| plinabulin (BPI 2358) / BeyondSpring
A Bioinformatic Approach to the Clinical Evaluation of Linear Commitment Versus Cloud (Continuum of Low Primed UnDifferentiated) Models for Hematopoiesis Using Plinabulin Clinical Trial Data () - Nov 29, 2022 - Abstract #ASH2022ASH_6941;
P3
Peripheral blood cell counts (PBCs) from the myeloid, lymphoid, and erythroid lineages in cancer pts receiving myelosuppressive chemotherapy (Chemo) with and without Plin were analyzed using bioinformatics.MethodPBCs from cancer pts (Breast, NSCLC, HRPC) receiving Chemo (TAC [docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2; Study 106; NCT03294577] or docetaxel 75 mg/m2 alone; Study 105 NCT03102606), with Plin doses of 5, 10, 20, 30 mg/m2 (or equivalent) or placebo (Plac; without plinabulin) were collected at screening, predose (cycle (C) 1 day (D) 1,) and at 24 hours after Chemo with or without Plin (C1D2)...All pts (with and without Plin) had received dexamethasone 16 mg per day on D-1, 1, and 2 as premedication for docetaxel (and TAC)...The data also suggests a degree of protective effect with Plin on CLP- and MEP-cells. The interdependence in abundance of mature PBCs derived from GMP cells, but also from CLP- and MEP-derived cells, is strongly supportive of Lineage Commitment.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Aggressive Mantle Cell Lymphoma with Neurolymphomatosis and Cutaneous Infiltration: First Case Report and Review of Literature () - Nov 29, 2022 - Abstract #ASH2022ASH_7404;
He received treatment with dexamethasone and PLEX with no improvement...Most cases were treated with systemic chemotherapy with R-CHOP and high dose Methotrexate...MRI is the diagnostic modality of choice, which was instrumental in establishing diagnosis in our case and further workup was not felt necessary. Novel CART-cell therapy and consolidative therapies such as high dose chemotherapy followed by stem cell transplant (HDC- ASCT) should be considered in appropriate cases, as we intended in our case after disease stabilization.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: In vivo structural modification of type II arabinogalactans with fungal endo-β-1, 6-galactanase in Arabidopsis. (Pubmed Central) - Nov 29, 2022
We generated transgenic Arabidopsis plants expressing a fungal endo-β-1,6-galactanase, Tv6GAL, that degrades long side chains specifically under the control of dexamethasone (Dex)...Tv6GAL induction caused retarded growth of seedlings, which had a reduced amount of cellulose in cell walls. These results suggest that long β-1,6-galactan side chains are necessary for normal cellulose synthesis and/or deposition as their defect affects cell growth in plants.
- |||||||||| dexamethasone / Generic mfg.
Journal: Association Between Aldosterone and Hypertension Among Patients With Overt and Subclinical Hypercortisolism. (Pubmed Central) - Nov 29, 2022
This single-center retrospective cohort study included patients with adrenal tumor and serum cortisol levels after 1-mg dexamethasone suppression test >1.8 µg/dL (50 nmol/L)...These findings indicate that aldosterone may contribute to hypertension among patients with subclinical hypercortisolism. Further multi-institutional and population-based studies are required to validate our findings and examine the clinical effectiveness of the intervention targeting aldosterone for such patients.
- |||||||||| hydrocortisone / Generic mfg.
Review, Journal: Current role of high dose vitamin C in sepsis management: A concise review. (Pubmed Central) - Nov 29, 2022
Initial trials showed improved patient outcomes when high dose vitamin C was used in combination with thiamine and hydrocortisone...However, subsequent large-scale randomised control trials could not replicate these results, leaving the world divided regarding the role of vitamin C in sepsis management. Here, we discuss the rationale, safety profile, and the current clinical evidence for the use of high-dose vitamin C in the management of sepsis and septic shock.
- |||||||||| dexamethasone / Generic mfg.
Journal: Effect of a recent parenteral dexamethasone and ketoprofen administration on the immunological diagnosis of tuberculosis in goats. (Pubmed Central) - Nov 29, 2022
Dexamethasone and ketoprofen detection in either hair or serum samples was challenging when using HPLC since these substances were not detected in animals whose skin fold thickness (SFT) was reduced, what could be an issue if they are used for fraudulent purposes. In conclusion, the parenteral administration of dexamethasone or ketoprofen 48 h after the PPDs administration can significantly reduce the increase in SFT (mm) and subsequently the number of positive reactors to SIT test.
|
